NicOx spikes on successful glaucoma drug study

Shares of France's NicOx spiked on the news that its experimental glaucoma drug licensed to Bausch & Lomb proved positive in a mid-stage study. According to their release two of the four doses used in the trial worked better than Pfizer's ($PFE) Xalatan to reduce eye-fluid pressure. The upbeat news is a welcome relief for NicOx, which was hammered last year after big regulatory setbacks in the U.S. and Europe for naproxcinod. Story

Suggested Articles

While Sanofi is looking to move more of its R&D in-house, there is still room for deals, and today it’s penned a big one with Fierce 15 winner Kymera

Tranquis Therapeutics launched with $30 million to create a new class of medicines for illnesses like amyotrophic lateral sclerosis and Alzheimer’s.

Biogen unveiled full phase 1/2 for a prospect that emerged from a shift in its thinking about treating amyotrophic lateral sclerosis.